|
[1]
|
Pasquale, T.R. and Tan, J.S. (2005) Nonantimicrobial effects of antibacterial agents. Clinical Infectious Diseases, 40, 127-135.
|
|
[2]
|
Guz, K. and Bugla-Plaskońska, G. (2007) The immunomodulatory and anti-inflammatory properties of diferent antimicrobial agents. Postepy Higieny i Medycyny Doswiadczalnej, 61, 828-837.
|
|
[3]
|
Kwiatkowska, B. and Mallińska, M. (2012) Macrolide therapy in chronic inflammatory diseases. Mediators of Inflammation, 2012, Article ID: 636157.
doi:10.1155/2012/636157
|
|
[4]
|
Brooks, B.M., Flanagan, B.F., Thomas, A.L. and Coleman, J.W. (2001) Penicillin conjugates to interferon-gamma and reduces its activity: A novel drug-cytokine interaction. Biochemical and Biophysical Research Communications, 288, 1175-1181.
|
|
[5]
|
Mangano, K., Quattrocchi, C., Scalia, G., Speciale, A., Nicoletti, G. and Di Marco, R. (2006) Immunomodulatory properties of cefaclor: In vivo effect on cytokine release and lymphoproliferative response in rats. Journal of Chemotherapy, 18, 641-647.
|
|
[6]
|
Tauber, S.C. and Nau, R. (2008) Immunomodulatory properties of antibiotics. Current Molecular Pharmacology, 1, 68-79.
|
|
[7]
|
Wenisch, C., Parschalk, B., Hasenhündl, M., Wiesinger, E. and Graninger, W. (1995) Effect of cefodizime and ceftriaxone on phagocytic function in patients with severe infections. Antimicrobial Agents and Chemotherapy, 39, 672-676. doi:10.1128/AAC.39.3.672
|
|
[8]
|
Alekshun, M.N. (2005) New advances In antibiotic development and discovery. Expert Opinion on Investigational Drugs, 14, 117-134.
doi:10.1517/13543784.14.2.117
|
|
[9]
|
Wilson, D.N. (2009) The A-Z of bacterial translation inhibitors. Critical Reviews in Biochemistry and Molecular Biology, 44, 393-433.
doi:10.3109/10409230903307311
|
|
[10]
|
Kanoh, S. and Rubin, B.K. (2010) Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clinical Microbiology Reviews, 23, 590-615. doi:10.1128/CMR.00078-09
|
|
[11]
|
Suzaki, H., Asano, K., Ohki, S., et al. (1999) Supressive activity of a macrolide antibiotic, roxitromycin, on proinflammatory cytokine production in vitro and in vivo. Mediators of Inflammation, 8, 199-204.
doi:10.1080/09629359990351
|
|
[12]
|
Shimane, T., Asano, K., Suzuki, M., et al. (2001) Influence of a macrolide antibiotic, roxitromycin, on mast cell growth and activation in vitro. Mediators of Inflammation, 10, 323- 332. doi:10.1080/09629350120102343
|
|
[13]
|
Schultz, M.J., Speelman, P., Hack, C.R., et al. (2000) Intravenous infusion of erythromycin inhibits CXC chemokine production, but augments neutrophil degranulation in whole blood stimulated with Streptococcus pneumoniae. Journal of Antimicrobial Chemotherapy, 46, 235- 240. doi:10.1093/jac/46.2.235
|
|
[14]
|
Matsuoka, N., Eguchi, K., Kawakami, A., et al. (1996) Inhibitory effect of clarithromycin on costimulatory molecule expression and cytokine production by synovial fibroblast-like cells. Clinical & Experimental Immunology, 104, 501-508. doi:10.1046/j.1365-2249.1996.46752.x
|
|
[15]
|
Keicho, N., Kudoh, S., Yotsumo, H., et al. (1993) Antilymphocytic activity of erythromycin distinct from that of FK506 or cyclosporine A. The Journal of Antibiotics, 46, 1406-1413. doi:10.7164/antibiotics.46.1406
|
|
[16]
|
Sato, E., Nelson, D.K., Koyama, J., et al. (2000) Erythromycin modulates eosinophil chemotactic cytokine production by lung fibroblasts in vitro. Antimicrobial Agents and Chemotherapy, 45, 401-406.
doi:10.1128/AAC.8.2.401-406.2001
|
|
[17]
|
Ogrendik, M. (2009) Efficacy of roxitromycin in adult patients with rheumatoid arthritis who had not received disease-modifying antirheumatic drugs: A 3-month, randomized, double-blind, placebo-controlled trial. Clinical Therapeutics, 31, 1754-1764.
doi:10.1016/j.clinthera.2009.08.014
|
|
[18]
|
Oyama, K., Sakuta, T., Matsushita, K., Maruyama, I., Nagaoka, S. and Torii, M. (2000) Effects of roxithromycin on tumor necrosis factor-alpha-induced vascular endothelial growth factor expression in human periodontal ligament cells in culture. Journal of Periodontology, 71, 1546- 1553doi:10.1902/jop.2000.71.10.1546
|
|
[19]
|
Ogrendik, M. (2007) Effects of clarithromycin in patients with active rheumatoid arthritis. Current Medical Research and Opinion, 23, 515-522.
doi:10.1185/030079906X167642
|
|
[20]
|
Sawiola, G., Benucci, M., Abdi-Ali, L., Baiardi, P., Manferdi, M., Bucci, M. and Cirino, G. (2010) Clarithromycin in adult-onset Still’s disease: A study of 6 cases. Rheumatology International, 30, 555-560.
doi:10.1007/s00296-009-1277-9
|
|
[21]
|
Thanou-Stavraki, A., Aberle, T., Aksentijevich, I., Bane, B.L. and Harley, J.B. (2011) Clarithromycin in adult-on- set still’s disease: A potentially useful therapeutic. Journal of Clinical Rheumatology, 17, 373-376.
doi:10.1097/RHU.0b013e3182320680
|
|
[22]
|
Carevic, O. and Djokic, S. (1988) Comparative studies on the effects of erythromycin A and azithromycin upon extracellular release of lysosomal enzymes in inflammatory processes. Agents and Actions, 25, 124-131.
doi:10.1007/BF01969103
|
|
[23]
|
Mencarelli, A., Distrutti, E., Renga, B., et al. (2011) Development of non-anticiotic macrolide that corrects inflammation-driven immune dysfunction in models of inflammatory bowel diseases and arthritis. European Journal of Pharmacology, 665, 29-39.
|
|
[24]
|
Eisen, H.J., Tuzcu, E.M., Dorent, R., et al. (2003) Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. The New England Journal of Medicine, 349, 847-858.
|
|
[25]
|
Blagosklonny, M.V. (2011) Progeria, rapamycin and normal aging: Recent breakthrough. Aging, 3, 685-691.
|
|
[26]
|
Calleja, C., Pascussi, J.M., Mani, J.C., Maurel, P. and Vilarem, M.J. (1998) The antibiotic rifampicin is a nonsteroidal ligand and activator of the human glucocorticoid receptor. Nature Medicine, 4, 92-96.
doi:10.1038/nm0198-092
|
|
[27]
|
Herr, A.S., Wochnik, G.M., Rosenhagen, M.C., Holsboer, F. and Rein, T. (2000) Rifampicin is not an activator of glucocorticoid receptor. Molecular Pharmacology, 57, 732- 737.
|
|
[28]
|
Sapadin, A.N. and Fleischmajer, R. (2006) Tetracyclines: Nonantibiotic properties and their clinical implications. Journal of the American Academy of Dermatology, 54, 258-265. doi:10.1016/j.jaad.2005.10.004
|
|
[29]
|
Golub, L.M., Lee, H.M., Lehrer, G., Nemiroff, A., Mc- Namara, T.F., Kaplan, R., et al. (1983) Minocycline reduses gingival collagenolytic activity during diabetes. Preliminary observations and a proposed new mechanism of action. Journal of Periodontal Research, 18, 516-526.
doi:10.1111/j.1600-0765.1983.tb00388.x
|
|
[30]
|
Kloppenburg, M., Verweij, C.L., Miltenburg, A.M.M., Verhoeven, A.J., Daha, M.R., Dijkmans, B.A.C. and Breedveld, F.C. (1995) The influence of tetracyclines on T cell activation. Clinical & Experimental Immunology, 102, 635-641. doi:10.1111/j.1365-2249.1995.tb03864.x
|
|
[31]
|
Greenwald, R.A., Golub, L.M., Lavities, B., Ramamurthy, N.S., Gruber, B., Laskin, R.S. and McNamara, T.F. (1987) Tetracyclines inhibit human synovial collagenase in Vivo and in Vitro. The Journal of Rheumatology, 14, 28-32.
|
|
[32]
|
Schnabel, L.V., Papich, M.G., Watts, A.E. and Fortier L.A. (2010) Orally administred doxycycline accumulates in synovial fluid compared to plasma. Equine Veterinary Journal, 42, 208-210. doi:10.2746/042516409X478514
|
|
[33]
|
Kloppenburg, M., Breedveld, F.C., Terwiel, J.Ph., Mallee, C. and Dijkmans, B.A.C. (1994) Minocycline in active rheumatoid arthritis. A double-blind, plcebo-controlled trial. Arthritis & Rheumatism, 37, 629-636.
doi:10.1002/art.1780370505
|
|
[34]
|
O’Dell, J.R., Haire, C.E., Palmer, W., Drymalski, W., Wees, S., Blakely, K., Churchill, M., Eckhoff, P.J., Weaver, A., Doud, D., Erikson, N., Diez, F., Olson, R., Maloley, P., Klassen, L.W. and Moore, G. (1997) Reatment of early rheumatoid arthritis with minocycline or placebo. Result of a randomized, double blind, placebo-controlled trial. Arthritis & Rheumatism, 40, 842-848.
doi:10.1002/art.1780400510
|
|
[35]
|
Stone, M., Fortin, P.R., Pacheco-Tena, C. and Inman, R.D. (2003) Should tetracycline treatment be used more extensively for rheumatoid arthritis? Metaanalysis demonstrates clinical benefit with reduction in disease activity. The Journal of Rheumatology, 30, 2112-2122.
|
|
[36]
|
O’Dell, J.R., Blakely, K.W., Mallek, J.A., Eckhoff, P.J., Leff, R.D., Sems, K.M., Fernandez, A.M., Palmer, W.R., Klassen, L.W., Paulsen, G.A., Hair, C.E. and Moore G.F. (2001) Treatment of early seropositive rheumatoid arthritis: A two-year, double-blind comparison of minocycline and hydroxychloroquine. Arthritis & Rheumatism, 44, 2235-2241.
doi:10.1002/1529-0131(200110)44:10<2235::AID-ART385>3.0.CO;2-A
|
|
[37]
|
Laasila, K., Laasonen, L. and Leirisalo-Repo, M. (2003) Antibiotic treatment and long term prognosis of reactive arthritis. Annals of the Rheumatic Diseases, 62, 655-658.
doi:10.1136/ard.62.7.655
|
|
[38]
|
Yu, L.P., Smith, G.N., Brandt, K.D., Myers, S.L., O’Connor, B.L. and Brandt, D.A. (1992) Reduction of the severity of cannine osteoartthritis by prophylactic treatment with oral doxycycline. Arthritis & Rheumatism, 35, 1150- 1159. doi:10.1002/art.1780351007
|
|
[39]
|
Lokeshwar, B.L. (2001) Chemically modified non antimicrobial tetracyclines are multifunctional drugs against advanced cancers. Pharmacolgical Research, 63, 146- 150. doi:10.1016/j.phrs.2010.11.003
|
|
[40]
|
Lokeshwar, B.L., Houston-Clark, H.L., Selzer, M.G., Block, N.L. and Golub, L.M. (1998) Potential application of a chemically modified non antimicrobial tetracycline (CMT- 3) against metastatic prostate cancer. Advances in Dental Research, 12, 97-102.
|
|
[41]
|
Castro, M.M., Rizzi, E., Figueiredo-Lopes, L., Fernandes, K., Bendhack, L.M., Pitol, D.L., et al. (2008) Aetalloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats. Atherosclerosis, 198, 320-331.
doi:10.1016/j.atherosclerosis.2007.10.011
|
|
[42]
|
Creemers, E.E., Cleutjens, J.P., Smith, J.F. and Daemen, M.J. (2001) Matrix metalloproteinase inhibition after myocardial infarction: A new approach to prevent heart failure? Circulation Research, 89, 201-210.
doi:10.1161/hh1501.094396
|
|
[43]
|
Castro, M.M., Kandasamy, A.D., Youssef, N. and Schulz, R. (2011) Matrix metalloproteinase inhibitor properties of tetracyclines: Therapeutic potential in cardiovascular diseases. Pharmacologycal Research, 64, 551-560.
doi:10.1016/j.phrs.2011.05.005
|
|
[44]
|
Cena, J.J., lalu, M.M., Cho, W.J., Chow, A.K., Bagdan, M.L., Daniel, E.E., et al. (2009) Inhibition of matrix metalloproteinase activity in vivo protects against vascular hyporeactivity in endotoxemia. American Journal of Physiology-Heart and Circulatory Physiology, 298, 45- 51.
doi:10.1152/ajpheart.00273.2009
|
|
[45]
|
Li, M., Ona, V.O., Chen, M., Kaul, M., Tenneti, L., Zhang, X., et al. (2009) Functional role and therapeutic implications of neuronal caspase-1 and-3 in a mouse model of traumatic spinal cord injury. Neuroscience, 99, 333-342. doi:10.1016/S0306-4522(00)00173-1
|
|
[46]
|
Sanchez, M.R.O., Ona, V.O, Li, M. and Friedlander, R.M. (2001) Minocycline reduces traumatic brain injury-mediated caspase-1 activation, tissue damage and neurogical dysfunction. Neurosurgery, 48, 1393-1401.
|
|
[47]
|
Lai, A.Y. and Todd, K.G. (2006) Hipoxia-activated microglial mediators of neuronal survival are differentially regulated by tetracyclines. Glia, 53, 809-816.
doi:10.1002/glia.20335
|
|
[48]
|
Brundula, V., Rewcastle, N.B., Metz, L.M., Bernard, C.C. and Yong, V.W. (2002) Targeting leucocyte MMPs and transmigration: Minocycline as a potential therapy for multiple sclerosis. Brain, 125, 1297-1308.
doi:10.1093/brain/awf133
|
|
[49]
|
Bastos, L.F.S., De Oliveira, A.C.P., Watkins, L.R., Moraes, M.F.D. and Coelho, M.M. (2012) Tetracyclines and pain. Naunyn-Schmiedeberg’s Archives of Pharmacology, 385, 225-241. doi:10.1007/s00210-012-0727-1
|
|
[50]
|
Miyazaki, E., Ando, M., Fukami, T., Nureki, S., Eishi, E., Kumamoto, T. (2008) Minocycline for the treatment of sarcoidosis: In the mechanism of action immunomodulating or antimicrobial effect? Clinical Rheumatology, 27, 1195-1197. doi:10.1007/s10067-008-0903-3
|
|
[51]
|
Agostini, C., Cassatella, M., Zembello, R., et al. (1998) Involment if the IP-10 chemokine in sarcoid granulomatous reaction. Journal of Immunology, 161, 6413-6420.
|
|
[52]
|
Le, C.H., Morales, A. and Trentham, D.E. (1998) Minocycline in early diffuse scleroderma. Lancet, 28, 1755- 1756.
|
|
[53]
|
Singer, I. and Rosenberg, D. (1973) Demociline induced nephrogenic diabetes insipidus: In vivo and in vitro studies. Annals of Internal Medicine, 79, 679-683.
doi:10.7326/0003-4819-79-5-679
|
|
[54]
|
Cherrill, D.A., Stote, R.M., Birge, J.R. and Singe, I. (1975) Demeclocycline treatment in the syndrome of inappropriate antidiuretic hormone secretion. Annals of Internal Medicine, 83, 654-656.
doi:10.7326/0003-4819-83-5-654
|
|
[55]
|
Kahn, A.A., Slifer, T.R. and Remington, J.S. (1998) Effect of Trovafloxacin on production of cytokinez by human monocytes Antimicrob. Agents Chemother, 42, 1713- 1717.
|
|
[56]
|
Lahat, G., Halperin, D., Barazovsky, E., Shalit, I. and Rabau, M. (2007) Immunomodulatory effects of ciprofloxacin in TNBS-induced colitis in mice. Inflammatory Bowel Diseases, 13, 557-565.
|
|
[57]
|
Hall, I.H., Schwab, U.E., Ward, E.S. and Ives, T.J. (2003) Effects of moxifloxacin in zymogen A or S. aureus stimulated human THP-1monocytes on the inflammatory process and the spread of infection. Life Sciences, 73, 2675-2685. doi:10.1016/S0024-3205(03)00611-8
|
|
[58]
|
Fernández, O. (2011) Oral laquinimod treatment in multiple sclerosis. Neurologia, 26, 111-117.
|
|
[59]
|
Gemmell, C.G., Peterson, Ph.K., Schmeling, D. and Kim, Y. (1981) Potentiation of opsonization and phagocytosis of Streptococcus pyogenes following growth in the presence of clindamycin. The Journal of Clinical Investigation, 67, 1249-1256.
|
|
[60]
|
Takahashi, G., Sato, N., Yaegashi, Y., et al. (2010) Effect of linezolid on cytokine production capacity and plasma endotoxin levels in response to lipopolysaccharide stimulation of whole blood. Journal of Infection and Chemotherapy, 16, 94-99.
|
|
[61]
|
Garcia-Roca, P., Mancilla-Ramirez, J., Santos-Segura, A., Fernández-Avilés, M. and Calderon-Jaimes. E. (2006) Linezolid diminishes inflammatory cytokine production from human peripheral blood mononuclear cells. Archives of Medical Research, 37, 31-35.
|
|
[62]
|
Pichereau, S., Moran, J.M.M., Hayney, M.S., Shukla, S.K., Sakoulas, G. and Rose W.E. (2012) Concentrationdependent effects of antimicrobials on Staphylococcus aureus toxin-mediated cytokine production from peripheral blood mononuclear cells. Journal of Antimicrobial Chemotherapy, 67, 123-129.
|
|
[63]
|
Müller, S., Eljack, S. and DelGaudio, J.M. (2011) Wegener’s Granulaomatosis. Head and Neck Pathology, 5, 268-272.
|
|
[64]
|
Brom, C., Brom, J. and König, W. (1992) Neomycin induces stimulatory and inhibitory effects on leukotriene generation, guanine triphospatase activity, and actin polymeryzation within human neutrophils. Immunology, 75, 150-156.
|
|
[65]
|
Bendtzen, K., Diamant, M. and Faber, V. (1990) Fusidic acid, an immunosuppressive drug with functions similar to cyclosporin A. Cytokine, 2, 423-429.
|
|
[66]
|
Osman, M.O., El-Sefi, T., Lausten, S.B., Jacobsen, N.O.G., Larsen, C.G. and Jensen, S.I. (1998) Sodium fusidate and the cytokine response in an experimental model of acute pancreatitis. British Journal of Surgery, 85, 1487-1492.
|
|
[67]
|
Morikawa, K., Oseko, F.I., Morikawa, S. and Sawada, M. (1993) Immunosuppressive activity of fosfomycin on human T-lymphocyte function in Vitro. Antimicrobial Agents and Chemotherapy, 37, 2684-2687.
|
|
[68]
|
Zeitlinger, M., Marsik, C., Steiner, I., Sauermann, R., Seir, K., Jilma, B., Wagner, O. and Joukhadar, C. (2007) Immunomodulatory effects of fosfomycin in an endotoxin model in human blood. The Journal of Antimicrobial Chemotherapy, 59, 219-223.
|